Trial NCT05249816
Publication Toback S, medRxiv, 2023
Primary outcome on the report: The primary objective of this study was to assess the safety and immune response of a single booster dose of NVX-CoV2373 in comparison to a single booster dose of BBIBP-CorV. Immunogenicity was assessed by anti-Spike (anti-S) IgG antibodies and neutralizing antibodies against SARS-CoV-2 to ancestral (Wuhan) strain on days 0, 14, 28 and 180.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.